Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statins and the myocardium.

Seema Mital1, James K Liao

  • 1Division of Pediatric Cardiology, Columbia University, College of Physicians and Surgeons, New York, New York.

Seminars in Vascular Medicine
|April 30, 2005
PubMed
Summary

Statins, or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, offer heart benefits beyond cholesterol reduction. They inhibit cardiac hypertrophy and heart failure by blocking Rho GTPase pathways, reducing oxidative stress and improving heart function.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An X-linked long non-coding RNA, PTCHD1-AS, and the core features of autism.

Nature·2026
Same author

Advanced physiological maturation of human iPSC-derived cardiomyocytes using an algorithm-directed optimization of defined media components.

Nature communications·2026
Same author

Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy.

The New England journal of medicine·2026
Same author

Induction of adipocyte thermogenic program by Rho-associated coiled-coil containing kinase 2.

iScience·2026
Same author

Abnormal Lipid Signaling Characterizes Diastolic Dysfunction in Pediatric Cardiomyopathy.

JACC. Basic to translational science·2026
Same author

Recurrent Symptomatic Hemorrhage in Cerebral Cavernous Malformations After Discontinuation of Atorvastatin or Placebo.

Journal of the American Heart Association·2026

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Cardiac hypertrophy and heart failure are significant global health burdens.
  • Statins are primarily known for cholesterol-lowering effects but also impact cardiovascular health through other mechanisms.

Purpose of the Study:

  • To investigate the cholesterol-independent mechanisms by which statins inhibit cardiac hypertrophy and heart failure.
  • To elucidate the role of Rho GTPase inhibition by statins in cardiovascular protection.

Main Methods:

  • The study focuses on the molecular mechanisms of statin action, specifically their effects on Rho GTPase family members (Rac1 and RhoA).
  • It examines the impact of statin-mediated inhibition of Rac1 on NADPH oxidase and oxidative stress.
  • It investigates the consequences of RhoA inhibition, including Akt activation and nitric oxide synthase upregulation.

Main Results:

  • Statins inhibit Rac1, a key component of NADPH oxidase, thereby reducing cardiovascular oxidative stress and cardiac hypertrophy.
  • Statin-induced RhoA inhibition activates protein kinase B/Akt and upregulates Type 3 nitric oxide synthase.
  • These molecular changes lead to enhanced angiogenesis, improved myocardial perfusion, reduced apoptosis, and better endothelial and cardiac function.

Conclusions:

  • Statins exert beneficial cardiovascular effects through cholesterol-independent pathways involving Rho GTPase inhibition.
  • These mechanisms include reducing oxidative stress and promoting pro-angiogenic and cardioprotective signaling.
  • Statins may offer therapeutic potential for nonhyperlipidemic patients suffering from cardiac hypertrophy and heart failure.

Related Experiment Videos